Anti-TGF beta Receptor II antibody (ab61213)

Overview

  • Product nameAnti-TGF beta Receptor II antibody
    See all TGF beta Receptor II primary antibodies
  • Description
    Rabbit polyclonal to TGF beta Receptor II
  • SpecificityDetects endogenous levels of total TGF Beta RII protein.
  • Tested applicationsSuitable for: ELISA, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human, Pig
  • Immunogen

    Synthetic non-phosphopeptide derived from human TGF Beta RII around the phosphorylation site of serine 250 (D-R-SP-D-I). (Peptide available as ab134586.)

  • Positive control
    • Extracts from NIH/3T3 cells, human brain tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab61213 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/5000.
IHC-P 1/50 - 1/100.
WB 1/500 - 1/1000. Detects a band of approximately 63 kDa (predicted molecular weight: 63 kDa).Can be blocked with Human TGF beta Receptor II peptide (ab134586).

Target

  • FunctionTransmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.
  • Involvement in diseaseDefects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:614331]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases.
    Defects in TGFBR2 are a cause of esophageal cancer (ESCR) [MIM:133239].
    Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
    Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 2B (LDS2B) [MIM:610380]. An aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients. Note=TGFBR2 mutations Cys-460 and His-460 have been reported to be associated with thoracic aortic aneurysms and dissection (TAAD). This phenotype, also known as thoracic aortic aneurysms type 3 (AAT3), is distinguised from LDS2B by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit descending aortic disease and aneurysms of other arteries (PubMed:16027248), they have been considered as LDS2B by the OMIM resource.
  • Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.
  • Cellular localizationCell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AAT3 antibody
    • FAA3 antibody
    • LDS1B antibody
    • LDS2 antibody
    • LDS2B antibody
    • MFS2 antibody
    • RIIC antibody
    • TAAD2 antibody
    • TbetaR II antibody
    • TbetaR-II antibody
    • TGF beta receptor type 2 antibody
    • TGF beta receptor type II antibody
    • TGF beta receptor type IIB antibody
    • TGF beta type II receptor antibody
    • TGF-beta receptor type II antibody
    • TGF-beta receptor type-2 antibody
    • TGF-beta type II receptor antibody
    • TGF-beta-R2 antibody
    • TGFB R2 antibody
    • TGFbeta - RII antibody
    • TGFbeta RII antibody
    • Tgfbr2 antibody
    • TGFR-2 antibody
    • TGFR2_HUMAN antibody
    • Transforming growth factor beta receptor II antibody
    • Transforming growth factor beta receptor type II antibody
    • Transforming growth factor beta receptor type IIC antibody
    • Transforming growth factor, beta receptor II (70/80kDa) antibody
    • transforming growth factor, beta receptor II alpha antibody
    • transforming growth factor, beta receptor II beta antibody
    • transforming growth factor, beta receptor II delta antibody
    • transforming growth factor, beta receptor II epsilon antibody
    • transforming growth factor, beta receptor II gamma antibody
    • Transforming growth factor-beta receptor type II antibody
    see all

Anti-TGF beta Receptor II antibody images

  • All lanes : Anti-TGF beta Receptor II antibody (ab61213) at 1/500 dilution

    Lane 1 : extracts from NIH/3T3 cells
    Lane 2 : extracts from NIH/3T3 cells with immunizing peptide


    Predicted band size : 63 kDa
    Observed band size : 63 kDa
  • Ab61213 at 1/50-1/100 dilution staining human brain without (left) and with (right) blocking peptide; paraffin embedded.

References for Anti-TGF beta Receptor II antibody (ab61213)

This product has been referenced in:
  • Wang P  et al. Decorin reduces hypertrophic scarring through inhibition of the TGF-ß1/Smad signaling pathway in a rat osteomyelitis model. Exp Ther Med 12:2102-2108 (2016). WB ; Rat . Read more (PubMed: 27698699) »
  • Nurnberg ST  et al. Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap. PLoS Genet 11:e1005155 (2015). Mouse . Read more (PubMed: 26020946) »

See all 11 Publications for this product

Product Wall

Thank you for your call earlier this week and for your patience while I have been in touch with my colleagues regarding your enquiry.

The blocking peptide is now available as ab134586-

http://www.abcam.com/TGF-beta-Receptor-II-pepti...

Read More

Thank you for contacting us and reporting the problems encountered in using the anti-TGF beta Receptor II antibody (ab61213). We take product complaints very seriously, and investigate every product that we feel may not be performing correctly.
<...

Read More

Thank you very much for this valuable feedback!

As requested, I have issued a credit not for you to use for the other antibody (see below).

Having done this, I would like to reassure you that we have strict quality controls for al...

Read More

Thank you for taking the time to provide this further information. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody.

The details you have kindly provided will provide us with vital information for ...

Read More

Thank you for contacting us.

I am sorry to hear you have been experiencing problems with one of our antibodies. The quality of our products is important to us and I would like to reassure you that we investigate all customer complaints.
Read More

Thank you for contacting us.

This application of inhibition or blocking has not been tested with this antibody, but if you would like to try it, we have a testing discount program for that purpose. Please below for more details:

Fo...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (kidney)
Specification kidney
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: citrate buffer
Permeabilization No
Username

Dr. yong du

Verified customer

Submitted Jul 18 2008

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"